[Investigation of antitumor activity of the hexamer fraction of HLDF-6 peptide as a differentiation factor in hemoblastoma-bearing mice].
A study of antitumor properties of HLDF-6 was carried out in DBA/2 mice with transplantable ascites lympholeukemia P-388 as well as in tumor cell culture. Immunomodulating characteristics were evaluated. Five-fold administration of HLDF-6 peptide to tumor-bearing mice inhibited tumor growth thus extending survival. As a result metabolic activity decreased which was followed by longer survival of lympholeukemia P-388 cells and enhanced cytological effect of peritoneal macrophages on tumor cells of the same strain.
Danilenko
E D
ED
Sysoeva
G M
GM
Ustimenko
S Iu
SIu
Samukov
V V
VV
Kostanian
I A
IA
Masycheva
V I
VI
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D009842:Oligopeptides / Q000494:pharmacology*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D009842:Oligopeptides; C513648:threonyl-glycyl-glutamyl-asparaginyl-histidylarginine